Inventiva (NASDAQ:IVA) Shares Gap Up - Here's What Happened

Key Points

• Inventiva S.A. Sponsored ADR shares gapped up from $5.36 to $5.64 and last traded at $5.57, reflecting a trading increase of 3.5%.
• Several equities research analysts have given the stock an average rating of "Moderate Buy" with an average target price of $14.83, including upgrades from Piper Sandler and HC Wainwright.
• An institutional investor recently acquired a new position in Inventiva, purchasing 10,715 shares valued at approximately $32,000, indicating growing institutional interest in the company.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $5.36, but opened at $5.64. Inventiva shares last traded at $5.57, with a volume of 8,593 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently issued reports on IVA shares. HC Wainwright started coverage on shares of Inventiva in a report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price target on the stock. Guggenheim raised their price target on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Finally, Piper Sandler started coverage on shares of Inventiva in a report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price target on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.83.

Inventiva Trading Down 5.3%

The business's 50 day simple moving average is $4.15 and its 200 day simple moving average is $3.56.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.